Does the media refer more to AARD or OVID?

In the previous week, Aardvark Therapeutics had 20 more articles in the media than Ovid Therapeutics. MarketBeat recorded 24 mentions for Aardvark Therapeutics and 4 mentions for Ovid Therapeutics. Ovid Therapeutics' average media sentiment score of 1.30 beat Aardvark Therapeutics' score of 0.03 indicating that Ovid Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aardvark Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 23 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ovid Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, AARD or RLMD?

Relmada Therapeutics is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aardvark Therapeutics N/A N/A -$57.59M -$3.21 N/A Relmada Therapeutics N/A N/A -$57.38M -$0.90 N/A

Is AARD or RLMD more profitable?

Relmada Therapeutics' return on equity of -47.52% beat Aardvark Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aardvark Therapeutics N/A -71.54% -64.94% Relmada Therapeutics N/A -47.52% -43.97%

Does the media refer more to AARD or RLMD?

In the previous week, Aardvark Therapeutics had 17 more articles in the media than Relmada Therapeutics. MarketBeat recorded 24 mentions for Aardvark Therapeutics and 7 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 0.60 beat Aardvark Therapeutics' score of 0.03 indicating that Relmada Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aardvark Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 23 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Relmada Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Do analysts prefer CGC or AARD?

Aardvark Therapeutics has a consensus price target of $15.33, suggesting a potential upside of 167.60%. Given Aardvark Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aardvark Therapeutics is more favorable than Canopy Growth. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Canopy Growth 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.20 Aardvark Therapeutics 2 Sell rating(s) 4 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.42

Does the media refer more to AARD or BIOA?

In the previous week, Aardvark Therapeutics had 19 more articles in the media than BioAge Labs. MarketBeat recorded 24 mentions for Aardvark Therapeutics and 5 mentions for BioAge Labs. BioAge Labs' average media sentiment score of 1.39 beat Aardvark Therapeutics' score of 0.03 indicating that BioAge Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aardvark Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 23 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BioAge Labs 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, AARD or AVIR?

Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aardvark Therapeutics N/A N/A -$57.59M -$3.21 N/A Atea Pharmaceuticals N/A N/A -$158.35M -$2.08 N/A

Is AARD or AVIR more profitable?

Atea Pharmaceuticals' return on equity of -64.25% beat Aardvark Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aardvark Therapeutics N/A -71.54% -64.94% Atea Pharmaceuticals N/A -64.25% -57.12%

Does the media refer more to AARD or AVIR?

In the previous week, Aardvark Therapeutics had 22 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 24 mentions for Aardvark Therapeutics and 2 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 1.70 beat Aardvark Therapeutics' score of 0.03 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aardvark Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 23 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Atea Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Aardvark Therapeutics (AARD) Competitors

$5.73 -0.22 (-3.70%)

As of 09/3/2026 04:00 PM Eastern

Compare

AARD vs. OVID, RLMD, CGC, BIOA, and AVIR

Should you buy Aardvark Therapeutics stock or one of its competitors? Aardvark Therapeutics's main competitors and comparable companies include Ovid Therapeutics (OVID), Relmada Therapeutics (RLMD), Canopy Growth (CGC), BioAge Labs (BIOA), and Atea Pharmaceuticals (AVIR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Aardvark Therapeutics compare to Ovid Therapeutics?

Aardvark Therapeutics (NASDAQ:AARD) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, media sentiment, profitability, dividends, risk and institutional ownership.

Aardvark Therapeutics has a beta of 3.74, suggesting that its share price is 274% more volatile than the broader market. Comparatively, Ovid Therapeutics has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market.

Aardvark Therapeutics currently has a consensus target price of $15.33, suggesting a potential upside of 167.60%. Ovid Therapeutics has a consensus target price of $5.86, suggesting a potential upside of 110.69%. Given Aardvark Therapeutics' higher probable upside, equities research analysts clearly believe Aardvark Therapeutics is more favorable than Ovid Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.42
Ovid Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

In the previous week, Aardvark Therapeutics had 20 more articles in the media than Ovid Therapeutics. MarketBeat recorded 24 mentions for Aardvark Therapeutics and 4 mentions for Ovid Therapeutics. Ovid Therapeutics' average media sentiment score of 1.30 beat Aardvark Therapeutics' score of 0.03 indicating that Ovid Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aardvark Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	23 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ovid Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ovid Therapeutics has higher revenue and earnings than Aardvark Therapeutics. Ovid Therapeutics is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A
Ovid Therapeutics	$7.25M	74.89	-$17.41M	-$0.31	N/A

72.2% of Ovid Therapeutics shares are held by institutional investors. 17.8% of Aardvark Therapeutics shares are held by insiders. Comparatively, 7.0% of Ovid Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Aardvark Therapeutics has a net margin of 0.00% compared to Ovid Therapeutics' net margin of -240.11%. Ovid Therapeutics' return on equity of -23.64% beat Aardvark Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aardvark Therapeutics	N/A	-71.54%	-64.94%
Ovid Therapeutics	-240.11%	-23.64%	-20.52%

Summary

Ovid Therapeutics beats Aardvark Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Aardvark Therapeutics compare to Relmada Therapeutics?

Aardvark Therapeutics (NASDAQ:AARD) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, media sentiment, dividends, valuation and earnings.

In the previous week, Aardvark Therapeutics had 17 more articles in the media than Relmada Therapeutics. MarketBeat recorded 24 mentions for Aardvark Therapeutics and 7 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 0.60 beat Aardvark Therapeutics' score of 0.03 indicating that Relmada Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aardvark Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	23 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Relmada Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Aardvark Therapeutics presently has a consensus target price of $15.33, indicating a potential upside of 167.60%. Relmada Therapeutics has a consensus target price of $12.00, indicating a potential upside of 174.60%. Given Relmada Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Relmada Therapeutics is more favorable than Aardvark Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.42
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Relmada Therapeutics is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A
Relmada Therapeutics	N/A	N/A	-$57.38M	-$0.90	N/A

Relmada Therapeutics' return on equity of -47.52% beat Aardvark Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aardvark Therapeutics	N/A	-71.54%	-64.94%
Relmada Therapeutics	N/A	-47.52%	-43.97%

Aardvark Therapeutics has a beta of 3.74, meaning that its share price is 274% more volatile than the broader market. Comparatively, Relmada Therapeutics has a beta of 0.45, meaning that its share price is 55% less volatile than the broader market.

45.2% of Relmada Therapeutics shares are owned by institutional investors. 17.8% of Aardvark Therapeutics shares are owned by insiders. Comparatively, 14.5% of Relmada Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Relmada Therapeutics beats Aardvark Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Aardvark Therapeutics compare to Canopy Growth?

Canopy Growth (NASDAQ:CGC) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

Aardvark Therapeutics has a consensus price target of $15.33, suggesting a potential upside of 167.60%. Given Aardvark Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Aardvark Therapeutics is more favorable than Canopy Growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Canopy Growth	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.42

Canopy Growth has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market. Comparatively, Aardvark Therapeutics has a beta of 3.74, suggesting that its share price is 274% more volatile than the broader market.

In the previous week, Aardvark Therapeutics had 24 more articles in the media than Canopy Growth. MarketBeat recorded 24 mentions for Aardvark Therapeutics and 0 mentions for Canopy Growth. Canopy Growth's average media sentiment score of 0.58 beat Aardvark Therapeutics' score of 0.03 indicating that Canopy Growth is being referred to more favorably in the media.

Company	Overall Sentiment
Canopy Growth	Positive
Aardvark Therapeutics	Neutral

Aardvark Therapeutics has lower revenue, but higher earnings than Canopy Growth. Canopy Growth is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Canopy Growth	$251.01M	1.74	-$190.29M	-$0.45	N/A
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A

3.3% of Canopy Growth shares are held by institutional investors. 0.4% of Canopy Growth shares are held by insiders. Comparatively, 17.8% of Aardvark Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Aardvark Therapeutics has a net margin of 0.00% compared to Canopy Growth's net margin of -65.33%. Canopy Growth's return on equity of -21.91% beat Aardvark Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Canopy Growth	-65.33%	-21.91%	-14.34%
Aardvark Therapeutics	N/A	-71.54%	-64.94%

Summary

Aardvark Therapeutics beats Canopy Growth on 10 of the 16 factors compared between the two stocks.

How does Aardvark Therapeutics compare to BioAge Labs?

Aardvark Therapeutics (NASDAQ:AARD) and BioAge Labs (NASDAQ:BIOA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, valuation, risk, dividends, analyst recommendations and institutional ownership.

Aardvark Therapeutics currently has a consensus price target of $15.33, suggesting a potential upside of 167.60%. BioAge Labs has a consensus price target of $36.57, suggesting a potential upside of 284.96%. Given BioAge Labs' stronger consensus rating and higher probable upside, analysts clearly believe BioAge Labs is more favorable than Aardvark Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.42
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Aardvark Therapeutics has a beta of 3.74, indicating that its stock price is 274% more volatile than the broader market. Comparatively, BioAge Labs has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market.

Aardvark Therapeutics has higher earnings, but lower revenue than BioAge Labs. BioAge Labs is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A
BioAge Labs	$8.99M	48.50	-$80.61M	-$2.38	N/A

Aardvark Therapeutics has a net margin of 0.00% compared to BioAge Labs' net margin of -912.26%. BioAge Labs' return on equity of -28.99% beat Aardvark Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aardvark Therapeutics	N/A	-71.54%	-64.94%
BioAge Labs	-912.26%	-28.99%	-27.09%

In the previous week, Aardvark Therapeutics had 19 more articles in the media than BioAge Labs. MarketBeat recorded 24 mentions for Aardvark Therapeutics and 5 mentions for BioAge Labs. BioAge Labs' average media sentiment score of 1.39 beat Aardvark Therapeutics' score of 0.03 indicating that BioAge Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aardvark Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	23 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioAge Labs	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BioAge Labs beats Aardvark Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Aardvark Therapeutics compare to Atea Pharmaceuticals?

Aardvark Therapeutics (NASDAQ:AARD) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, earnings, institutional ownership, profitability, valuation and risk.

Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than Aardvark Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A
Atea Pharmaceuticals	N/A	N/A	-$158.35M	-$2.08	N/A

86.7% of Atea Pharmaceuticals shares are held by institutional investors. 17.8% of Aardvark Therapeutics shares are held by insiders. Comparatively, 21.6% of Atea Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Aardvark Therapeutics had 22 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 24 mentions for Aardvark Therapeutics and 2 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 1.70 beat Aardvark Therapeutics' score of 0.03 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aardvark Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	23 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Atea Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Aardvark Therapeutics currently has a consensus target price of $15.33, suggesting a potential upside of 167.60%. Atea Pharmaceuticals has a consensus target price of $7.00, suggesting a potential upside of 20.27%. Given Aardvark Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Aardvark Therapeutics is more favorable than Atea Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.42
Atea Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Aardvark Therapeutics has a beta of 3.74, indicating that its stock price is 274% more volatile than the broader market. Comparatively, Atea Pharmaceuticals has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market.

Atea Pharmaceuticals' return on equity of -64.25% beat Aardvark Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aardvark Therapeutics	N/A	-71.54%	-64.94%
Atea Pharmaceuticals	N/A	-64.25%	-57.12%

Summary

Aardvark Therapeutics beats Atea Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

Get Aardvark Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AARD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AARD vs. The Competition

Export

Metric	Aardvark Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$130.21M	$12.25B	$7.26B	$12.73B
Dividend Yield	N/A	2.59%	2.53%	8.86%
P/E Ratio	-1.79	787.27	273.29	25.38
Price / Sales	N/A	753.79	613.45	92.55
Price / Cash	N/A	94.80	77.82	52.26
Price / Book	1.68	12.33	12.89	6.14
Net Income	-$57.59M	$2.82B	$3.47B	$349.01M
7 Day Performance	-1.04%	2.59%	0.60%	-0.27%
1 Month Performance	-21.18%	6.95%	5.73%	0.68%
1 Year Performance	-32.51%	9.45%	25.35%	14.84%

Aardvark Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AARD Aardvark Therapeutics	2.8675 of 5 stars	$5.73 -3.7%	$15.33 +167.6%	-30.0%	$130.21M	N/A	N/A	18	Trending News
OVID Ovid Therapeutics	2.3991 of 5 stars	$2.80 -4.4%	$5.71 +104.1%	+109.0%	$572.22M	$7.25M	N/A	60	Positive News Analyst Forecast Gap Down
RLMD Relmada Therapeutics	2.2724 of 5 stars	$4.33 -4.2%	$12.00 +177.1%	+197.3%	$482.15M	N/A	N/A	10
CGC Canopy Growth	1.0171 of 5 stars	$1.00 -1.0%	N/A	-30.5%	$453.79M	$251.01M	N/A	1,128
BIOA BioAge Labs	3.8679 of 5 stars	$9.65 -4.3%	$36.57 +279.0%	+100.4%	$442.91M	$10.36M	N/A	N/A	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AARD) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aardvark Therapeutics (AARD) Competitors

AARD vs. OVID, RLMD, CGC, BIOA, and AVIR

How does Aardvark Therapeutics compare to Ovid Therapeutics?

Summary

How does Aardvark Therapeutics compare to Relmada Therapeutics?

Summary

How does Aardvark Therapeutics compare to Canopy Growth?

Summary

How does Aardvark Therapeutics compare to BioAge Labs?

Summary

How does Aardvark Therapeutics compare to Atea Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AARD vs. The Competition

Aardvark Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aardvark Therapeutics (AARD) Competitors

AARD vs. OVID, RLMD, CGC, BIOA, and AVIR

How does Aardvark Therapeutics compare to Ovid Therapeutics?

Which has more risk & volatility, AARD or OVID?

Do analysts rate AARD or OVID?

Does the media refer more to AARD or OVID?

Which has preferable valuation and earnings, AARD or OVID?

Do insiders & institutionals hold more shares of AARD or OVID?

Is AARD or OVID more profitable?

Summary

How does Aardvark Therapeutics compare to Relmada Therapeutics?

Does the media refer more to AARD or RLMD?

Do analysts prefer AARD or RLMD?

Which has higher earnings and valuation, AARD or RLMD?

Is AARD or RLMD more profitable?

Which has more volatility and risk, AARD or RLMD?

Do institutionals and insiders believe in AARD or RLMD?

Summary

How does Aardvark Therapeutics compare to Canopy Growth?

Do analysts prefer CGC or AARD?

Which has more volatility & risk, CGC or AARD?

Does the media favor CGC or AARD?

Which has preferable earnings & valuation, CGC or AARD?

Do institutionals & insiders have more ownership in CGC or AARD?

Is CGC or AARD more profitable?

Summary

How does Aardvark Therapeutics compare to BioAge Labs?

Do analysts prefer AARD or BIOA?

Which has more risk & volatility, AARD or BIOA?

Which has preferable valuation & earnings, AARD or BIOA?

Is AARD or BIOA more profitable?

Does the media refer more to AARD or BIOA?

Summary

How does Aardvark Therapeutics compare to Atea Pharmaceuticals?

Which has stronger valuation & earnings, AARD or AVIR?

Do institutionals and insiders have more ownership in AARD or AVIR?

Does the media refer more to AARD or AVIR?

Do analysts rate AARD or AVIR?

Which has more volatility and risk, AARD or AVIR?

Is AARD or AVIR more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AARD vs. The Competition

Aardvark Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools